In general terms, the analysis of MGMT methylation is already a widely debated topic in the literature, emphasizing its role as an important factor to be analyzed in GBM, so much so that in the 2021 WHO standards, among the molecular cascade that dissects the diagnostic classification of CNS tumors, MGMT is already essential in cases of GBM as a predictive value for prognosis in these types of tumors and also for making therapeutic decisions [1]. The gene discussed is MGMT; the disease is central nervous system neoplasm.